<DOC>
	<DOCNO>NCT00845039</DOCNO>
	<brief_summary>The purpose study determine value add IMC-A12 irinotecan cetuximab patient metastatic colorectal cancer .</brief_summary>
	<brief_title>A Study Irinotecan Cetuximab With Without IMC-A12 Treatment People With Colon Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin Bevacizumab</brief_title>
	<detailed_description>The purpose study determine value add IMC-A12 irinotecan + cetuximab improve PFS 18 week date randomization patient metastatic K-RAS wild-type CRC progress oxaliplatin/bevacizumab-containing regimen .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Must consent study must sign date IRBapproved consent form conform federal institutional guideline preentry tumor sample submission central KRAS test study treatment Must ECOG performance status 0 , 1 , 2 Must metastatic CRC The CRC tumor metastatic tumor must KRAS wildtype determined central test Must document disease progression firstline therapy contain oxaliplatin bevacizumab Most recent treatment regimen must end ≥ 21 day prior randomization , clinically significant side effect associate previous therapy must resolve ≤ grade 1 exception neuropathy must resolve ≤ grade 2 Imaging chest , abdomen pelvis CT scan MRI must perform within 3 week prior randomization Must measurable disease , define least one lesion outside previous RT field accurately measure least one dimension ≥ 20mm conventional technique ≥ 10mm 5mm cut use spiral CT scan Evidence adequate bone marrow function : ANC ≥ 1200/mm3 , hemoglobin ≥ 9g/dL , platelet ≥ 100,000/mm3 Evidence adequate hepatic function . If liver metastasis : AST ≤ 2.5 x ULN , total bilirubin ≤ 1.5 x ULN lab . In presence liver metastasis : AST ≤ 5.0 x ULN , total bilirubin ≤ 1.5 x ULN lab Serum creatinine must ≤ 1.5 x ULN lab Must fast blood glucose &lt; 126mg/dL . Fasting define caloric intake least 8 hour Life expectancy le 12 week Diagnosis anal small bowel carcinoma Tumor consider surgeon amenable complete resection Previous radiation therapy &gt; 25 % bone marrow Radiation therapy sit measurable disease choose target lesion Radiological evidence and/or clinical sign symptom CNS metastases Any follow condition event : uncontrolled hypertension , define systolic BP &gt; 150mmHg diastolic BP &gt; 100 without antihypertensive medication ( patient hypertension wellcontrolled medication eligible ) ; unstable angina within 6 month randomization ; NYHA Class III IV cardiac disease ; myocardial infarction within 6 month randomization ; symptomatic arrhythmia ; CNS cerebrovascular ischemia ( TIA stroke ) within 6 month randomization Other malignancy unless patient consider diseasefree complete therapy malignancy ≥ 12 month prior randomization . Patients follow cancer eligible diagnose treat within past 12 month : carcinoma situ cervix , colon carcinoma situ , melanoma situ , basal cell squamous cell carcinoma skin Serious nonhealing wound , skin ulcer , bone fracture Any significant bleeding unless source bleeding resect History bleed diathesis coagulopathy ( patient stable anticoagulant therapy eligible ) Any evidence active infection Active inflammatory bowel disease Grade 3 4 diabetes mellitus define NCI 's CTCAE v 3.0 pancreatic endocrine : glucose intolerance ( patient diabetes control diet and/or oral medication eligible ) Symptomatic interstitial pneumonitis definitive evidence interstitial pneumonitis describe CT scan chest xray asymptomatic patient Any serious concomitant medical condition , opinion investigator , would compromise safety patient compromise patient 's ability participate study Previous hypersensitivity reaction monoclonal antibody Previous treatment irinotecan , cetuximab , agent specifically target IGF receptor Treatment investigational drug within 30 day prior randomization Pregnancy lactation time patient entry Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Metastatic K-RAS Wild-Type Carcinoma Colon Rectum</keyword>
</DOC>